clinical trial · NCT07048197
A Study to Assess Safety, Cellular Kinetics and Exploratory Efficacy of Rapcabtagene Autoleucel in Rheumatoid Arthritis and Sjogren's Disease
Rheumatoid Arthritis (RA) and Sjögren's Disease (SjD)Rapcabtagene autoleucel
brief summary
A study to assess safety, cellular kinetics and exploratory efficacy of rapcabtagene autoleucel in rheumatoid arthritis and Sjogren's disease
started
Jun 20, 2025
primary completion
Nov 1, 2028
completion
Nov 1, 2028
last updated
Mar 30, 2026
detailed description
The study is intended to assess safety, cellular kinetics and any early sign for efficacy of rapcabtagene autoleucel in participants with difficult-to-treat rheumatoid arthritis (D2T RA) and severe, refractory Sjogren's disease (srSjD) with organ involvement.
official title
An Open-label, Multi-center, Phase 1/2 Study to Assess Safety, Cellular Kinetics and Exploratory Efficacy of Rapcabtagene Autoleucel in Participants With Difficult-to-treat Rheumatoid Arthritis and Severe, Refractory Sjogren's Disease With Organ Involvement
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol